TAG:
cancer testing
PacBio Beefs Up with Purchase of Omniome for $800 Million
By Robert Michel | From the Volume XXVIII, No. 10 – July 26, 2021 Issue
FORWARD-LOOKING PATHOLOGISTS AND LAB ADMINISTRATORS understand that the next big game in medical laboratory testing will be assays built upon genome sequencing. They also know that several companies are racing to produce gene sequencing instruments that are faster, simpler, and less costly in order t…
Pap Test Errors in Ireland Attributed to Quest, CPL
By Joseph Burns | From the Volume XXV No. 10 – July 9, 2018 Issue
CEO SUMMARY: In Ireland, the big story in healthcare at the moment is the discovery that the nation’s cervical cancer screening program has failed hundreds of women who had pre-cancerous conditions or cervical cancer, but, as alleged in numerous court cases, their tests were inaccurate …
In Florida, More Tests Added to UHC’s Decision-Support Program
By Joseph Burns | From the Volume XXV No. 1 – January 2, 2018 Issue
IN THE FIRST BROAD EXPANSION OF ITS pilot decision-support program for clinical lab testing in Florida, UnitedHealthcare (UHC) will add genetic and molecular tests, drug tests, and pathology procedures, among other assays starting in two months. On March 1, UHC will expand its labor…
Six Years after Launch, Med Fusion Sold to Quest
By Joseph Burns | From the Volume XXIV No. 9 – June 26, 2017 Issue
CEO SUMMARY: In Dallas, the relatively short-lived lab company known as Med Fusion has a new owner. After seven years, the lab partnership of Baylor Scott and White, US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories decided to sell their ownership stakes to Qu…
Is New Cycle of Fraud Plaguing Lab Industry?
By Robert Michel | From the Volume XXII No. 12 – August 24, 2015 Issue
CEO SUMMARY: Taken collectively, the growing number of federal investigations of clinical lab companies and health insurer lawsuits against lab companies alleging fraudulent business practices signals a disturbing new trend for the lab industry. Although these allegations are lev…
Newer, Smaller Analyzers Will Bring Big Data to Labs
By Joseph Burns | From the Volume XXII No. 10 – July 13, 2015 Issue
CEO SUMMARY: Clinical laboratories of all sizes are poised to become the source of much of a hospital or health system’s “big data.” At many academic center labs, greater use of genetic and molecular testing requires that more space and more staff be devoted to data management. A…
Dealing with Realities of Changing Market
By Joseph Burns | From the Volume XXI No. 10 – July 21, 2014 Issue
CEO SUMMARY: Swift transformation of the American healthcare system is causing financial challenges for those clinical labs and pathology groups that have been slow to react to these developments. At NorDx Laboratories in Scarborough, Maine, the team is following the classic five rules fo…
Eastern Canada’s Latest Lab Errors Get Attention
By Joseph Burns | From the Volume XXI No. 4 – March 17, 2014 Issue
CEO SUMMARY: Authorities for Eastern Health in Newfoundland and Labrador province in Canada are conducting a root cause analysis after finding discrepancies in breast cancer testing that affected nine patients. Health officials said these cases were discovered as a result of an improved q…
Alberta Lab RFP, FTC, LabMD Biodiagnostic Lab Services Guilty Pleas
By Robert Michel | From the Volume XX No. 13 – September 30, 2013 Issue
ALBERTA PROVINCE MAY SOON BID $3 BILLION CLINICAL LAB CONTRACT NEWS LEAKED ON SEPTEMBER 19 that Alberta Health Services (AHS) is preparing to issue a request for proposal (RFP) to select a company to build a state-of-the clinical laboratory facility to serve…
Urologists Weigh in on Prostate Biopsy Testing
By Joseph Burns | From the Volume XX No. 3 – March 4, 2013 Issue
CEO SUMMARY: Based on an impressive number of 4,230,129 vials collected from 437,937 biopsies, the new study is expected to add fuel to the fire of the ongoing debate about the appropriate number of prostate biopsies physicians should collect and refer to pathology labs for cancer testing…
CURRENT ISSUE
Volume XXXII, No. 1 – January 6, 2025
The Dark Report examines how AI is being used to predict the outcomes of FDA LDT lawsuits. Also, this issue is Part Two of a series about boosting pathology compensation in different settings, including hospitals. Two experienced pathology consultants identify the most effective approaches when negotiating Part A pathology agreements with hospitals and health systems, along with how to use data to bolster these negotiations.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103
Email: info@darkreport.com
© 2025 The Dark Report. All rights reserved.